Home > Resources > Company Profiles > Protalix BioTherapeutics, Incorporated

Protalix BioTherapeutics, Incorporated (PLX)

EMAIL
PRINT
SHARE
TEXT SIZE:
SHARE
Send a copy to me

Separate multiple email addresses (max 20) with commas.

0/1500
Dr. David Aviezer, Ph.D. , CEO/President/Director
Industry: Healthcare
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME


Overview
News
People
Financials

Company Information

Dr. David Aviezer, Ph.D., CEO/President/Director

2 Snunit Street

Science Park

Carmiel, 20100

IS Map it

Phone: 97249889488

Fax: 97249889489

www.protalix.com



Overview

A biopharmaceutical company focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellExtm protein expression system.

Press Releases
News From Around the Web
News
powered by inform

Employees

Number of Employees: 104
Revenue per Employee: $0

Top Executives

Yossi Maimon, CPA, CFO/Treasurer/Secretary/Vice President
Dr. Einat Brill Almon, Ph.D., Divisional Vice President
Yaron Naos, Vice President, Divisional

Dr. Yoseph Shaaltiel, Ph.D., Divisional Executive VP/Director

Board of Directors

Yossi Maimon, CPA, CFO/Treasurer/Secretary/Vice President
Zeev Bronfeld, Director
Eli Hurvitz, Chairman of the Board/Director

Amos Bar-Shalev, Director
Eyal Sheratzki, Director
Dr. Yoseph Shaaltiel, Ph.D., Divisional Executive VP/Director

Financials

Quarterly
Annual

Income Statement 08/2008 05/2008 03/2008 11/2007
Sales -320 K. -262 K. -229 K. -253 K.
Gross Operating Profit 320 K. 262 K. 229 K. 253 K.
Operating Income before D & A (EBITDA) -4.58 Mil. -6 Mil. -5.79 Mil. -5.18 Mil.
Total Income Before Interest Expenses (EBIT) -4.23 Mil. -5.11 Mil. -5.13 Mil. -4.75 Mil.
Total Net Income -4.23 Mil. -5.11 Mil. -5.13 Mil. -4.75 Mil.
Basic EPS, Total -0.06 -0.07 -0.06 -0.07
Diluted EPS, Total -0.06 -0.07 -0.06 -0.07

BALANCE STATEMENT 08/2008 05/2008 03/2008 11/2007
Cash and Equivalents 53.36 Mil. 57.78 Mil. 61.81 Mil. 20.44 Mil.
Total Assets 55.28 Mil. 59.88 Mil. 63.17 Mil. 22.54 Mil.
Total Liabilities 4.34 Mil. 4.2 Mil. 3.76 Mil. 3.61 Mil.
Total Capitalization 56.51 Mil. 60.75 Mil. 63.68 Mil. 22.47 Mil.

Cash Flow 08/2008 05/2008 03/2008 11/2007
Net Cash From Continuing Operations -7.45 Mil. -3.81 Mil. -10.45 Mil. -6.59 Mil.
Net Cash From Investing Activities -1.98 Mil. -856 K. -2.44 Mil. -1.14 Mil.
Net Cash From Financing Activities -53 K. -17 K. 58.57 Mil. 12.79 Mil.
Net Change in Cash & Cash Equivalents -8.45 Mil. -4.03 Mil. 46.44 Mil. 5.06 Mil.

powered by Interactive Data

Income Statement 2008 2007 2006 2005
Sales -759 K. -502 K. 0 0
Gross Operating Profit 759 K. 502 K. 0 0
Operating Income before D & A (EBITDA) -23.81 Mil. -9.27 Mil. -93.3 K. -165.58 K.
Total Income Before Interest Expenses (EBIT) -22.48 Mil. -9.43 Mil. -74.93 K. -160.07 K.
Total Net Income -22.48 Mil. -9.39 Mil. -74.93 K. -160.07 K.
Basic EPS, Total -0.33 -0.32 -0.2 -0.5
Diluted EPS, Total -0.33 -0.32 -0.2 -0.5

BALANCE STATEMENT 2008 2007 2006 2005
Cash and Equivalents 61.81 Mil. 15.38 Mil. 985.24 K. 563.71 K.
Total Assets 63.17 Mil. 24.29 Mil. 987.36 K. 565.84 K.
Total Liabilities 3.76 Mil. 2.27 Mil. 72.93 K. 70.47 K.
Total Capitalization 63.68 Mil. 24.28 Mil. 914.43 K. 495.36 K.

Cash Flow 2008 2007 2006 2005
Net Cash From Continuing Operations -10.45 Mil. -5.09 Mil. -72.48 K. -168.12 K.
Net Cash From Investing Activities -2.44 Mil. -980 K. 0 552.36 K.
Net Cash From Financing Activities 58.57 Mil. 16.71 Mil. 494 K. 0
Net Change in Cash & Cash Equivalents 46.44 Mil. 10.64 Mil. 421.52 K. 384.23 K.

powered by Interactive Data







Related Companies by Market Cap
Company Name
Price
Change
Market Cap
Momenta Pharmaceuticals Inc
221.01 Mil.
Idera Pharmaceuticals, Incorporated
233.53 Mil.
Molecular Insight Pharmaceuticals, Incorporated
216.8 Mil.
Nabi Pharmaceuticals
215.89 Mil.

Company Profile Change Request

The data provided in our company profiles comes from third party information providers.

Also in Portfolio.com
Most Read
Most Emailed
Recently Commented